A recently completed randomized phase II study at the Hospital for Sick Children in Toronto indicates "superiority of dabrafenib plus trametinib as first systemic treatment for pediatric patients with low-grade glioma with BRAF V600 mutations as compared with carboplatin plus vincristine, the standard chemotherapy approach." Following randomization amongst 110 patients, follow-up after a median of 18.9 months indicated overall response in 47% of patients treated with dabrafenib plus trametinib compared to a 11% overall response in those patients treated with chemotherapy. Other benefits included longer progression-free survival and a lower rate of discontinuing treatment due to side effects.
To learn more about this study, click here.
Source mentioned: Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med 2023;389:1108-1120.
No comments:
Post a Comment